KITE PHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kitepharma.com
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 450
- Registration Number
- NCT06413498
- Locations
- 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Clinica Universidad de Navarra, Pamplona, Spain
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Conditions
- Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaRelapsed/Refractory Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 21
- Registration Number
- NCT06253663
- Locations
- 🇯🇵
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan
🇯🇵Chiba University Hospital, Chiba, Japan
🇯🇵Kyushu University Hospital, Fukuoka, Japan
Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma
- Conditions
- Relapsed/Refractory Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 39
- Registration Number
- NCT06079164
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
- Conditions
- Large B-cell LymphomaFollicular Lymphoma
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT05776160
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
- Conditions
- Mantle Cell LymphomaAcute Lymphoblastic Leukemia
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT05776134
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
- Conditions
- High-risk Large B-cell Lymphoma (LBCL)
- Interventions
- First Posted Date
- 2022-11-04
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 300
- Registration Number
- NCT05605899
- Locations
- 🇪🇸
Hospital Universitario Marqués de Valdecilla, Santander, Spain
🇪🇸Hospital Universitari Vall D'Hebron, Barcelona, Spain
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies
- Conditions
- Relapsed/Refractory Hairy Cell LeukemiaRelapsed/Refractory Burkitt LymphomaRelapsed/Refractory Waldenstrom MacroglobulinemiaRelapsed/Refractory Richter Transformation
- Interventions
- First Posted Date
- 2022-09-13
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 19
- Registration Number
- NCT05537766
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Georgetown University Medical Centre, Washington, District of Columbia, United States
🇮🇹IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna, Italy
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
- Conditions
- Relapsed or Refractory Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2022-07-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 30
- Registration Number
- NCT05459571
- Locations
- 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
- Conditions
- Multiple Myeloma
- Interventions
- Biological: anitocabtagene-autoleucel
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 110
- Registration Number
- NCT05396885
- Locations
- 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Northside Hospital, Inc, Atlanta, Georgia, United States
🇺🇸John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, New Jersey, United States
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
- Conditions
- Relapsed/Refractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 230
- Registration Number
- NCT05371093
- Locations
- 🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇫🇷Hopital Saint Eloi, Montpellier, France
🇫🇷Hopital Pitie-Salpetriere, Paris, France